Condensed Consolidated Statements of Assets and Liabilities - USD ($)	Sep. 30, 2025		Dec. 31, 2024
ASSETS
Investments at fair value	$ 13,809,636,000		$ 13,092,518,000
Cash and Cash Equivalent	249,891,000		229,606,000
Receivable from broker	11,175,000		4,807,000
Deferred financing costs	21,220,000		21,865,000
Receivable for investments	17,247,000		2,976,000
Receivable for shares sold	0		4,405,000
Derivative assets at fair value (Note 6)	41,912,000		3,995,000
Total assets	14,256,287,000		13,472,224,000
LIABILITIES
Debt (net of unamortized debt issuance costs of $35,046 and $34,877, respectively)	7,656,956,000		7,056,091,000
Payable for investments	5,663,000		19,277,000
Management fees payable (Note 3)	34,959,000		32,305,000
Income based incentive fees payable (Note 3)	31,254,000		38,708,000
Capital gains based incentive fees payable (Note 3)	0		0
Interest payable	58,367,000		53,958,000
Distribution payable	177,837,000		170,751,000
Board of Trustees’ fees payable	282,000		289,000
Accrued expenses and other liabilities	16,634,000		17,212,000
Total liabilities	7,986,711,000		7,395,703,000
Commitments and contingencies (Note 8)
NET ASSETS
Common Shares, $0.001 par value (unlimited shares authorized; 230,957,158 and 221,892,184 shares issued and outstanding, respectively)	231,000		222,000
Additional paid in capital	6,035,785,000		5,749,762,000
Distributable earnings (loss)	233,560,000		326,537,000
Total net assets	6,269,576,000		6,076,521,000
Total liabilities and net assets	$ 14,256,287,000		$ 13,472,224,000
Net asset value per share (in usd per share)	$ 27.15		$ 27.39
Affiliated Entity
LIABILITIES
Due to affiliates	$ 4,759,000		$ 7,112,000
Non-controlled/non-affiliated investments
ASSETS
Investments at fair value	13,770,027,000	[1],[2]	13,063,171,000	[3],[4]
Interest receivable from non-controlled/non-affiliated investments	105,197,000		112,046,000
Non-controlled/affiliated investments
ASSETS
Investments at fair value	39,609,000	[1],[2]	29,347,000	[3],[4]
Interest receivable from non-controlled/non-affiliated investments	$ 9,000		$ 6,000

[1] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in U.S. dollars. As of September 30, 2025, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.

[2] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), excluding Axsome Therapeutics, Inc. - Common Stock, and may be deemed to be “restricted securities.” As of September 30, 2025, the aggregate fair value of these securities is $13,808.0 million or 220.23% of the Company’s net assets. The initial acquisition dates have been included for such securities.

[3] All securities are exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and may be deemed to be “restricted securities.” As of December 31, 2024, the aggregate fair value of these securities is $13,092.5 million or 215.43% of the Company’s net assets. The initial acquisition dates have been included for such securities.

[4] Unless otherwise indicated, all debt and equity investments held by the Company (which such term “Company” shall include the Company’s consolidated subsidiaries for purposes of this Condensed Consolidated Schedule of Investments) are denominated in dollars. As of December 31, 2024, the Company had investments denominated in Canadian Dollars (CAD), Euros (EUR), British Pounds (GBP), Danish Krone (DKK), Swedish Krona (SEK), Norwegian Krone (NOK), and Australian Dollars (AUD). All debt investments are income producing unless otherwise indicated. All equity investments are non-income producing unless otherwise noted. Certain portfolio company investments are subject to contractual restrictions on sales. The total par amount (in thousands) is presented for debt investments, while the number of shares or units (in whole amounts) owned is presented for equity investments. Each of the Company’s investments is pledged as collateral, under one or more of its credit facilities unless otherwise indicated.